Given that 25% of AML and about 10% of MPN and MDS bare DNMT3A mutations, which are associated with increased risk of relapse and poor overall prognosis; being able to target DNMT3A and downstream signals from DNMT3A is a prudent therapeutic approach. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.